These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26622786)

  • 1. Genetic variability of DNA repair mechanisms influences treatment outcome of gastric cancer.
    Ding C; Zhang H; Chen K; Zhao C; Gao J
    Oncol Lett; 2015 Oct; 10(4):1997-2002. PubMed ID: 26622786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
    Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
    Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single nucleotide polymorphisms of nucleotide excision repair and homologous recombination repair pathways and their role in the risk of osteosarcoma.
    Jin G; Wang M; Chen W; Shi W; Yin J; Gang W
    Pak J Med Sci; 2015; 31(2):269-73. PubMed ID: 26101473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer.
    Zheng DL; Tang GD; Chen YN; Zhang T; Qin MB
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
    Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
    Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
    Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
    Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
    Ji WP; He NB
    Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer.
    Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX
    Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 and ERCC2 variants predict survival in gastric cancer patients.
    Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY
    PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma.
    Wang MJ; Zhu Y; Guo XJ; Tian ZZ
    Genet Mol Res; 2015 Sep; 14(3):11652-7. PubMed ID: 26436406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
    Zhang H; Ge J; Hong H; Bi L; Sun Z
    World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
    Sun Y; Wu Y; Li W; Kong Z; Zou X
    Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.
    Yu SN; Liu GF; Li XF; Fu BH; Dong LX; Zhang SH
    J Cell Biochem; 2017 Dec; 118(12):4782-4791. PubMed ID: 28520216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between
    Boldrin E; Malacrida S; Rumiato E; Battaglia G; Ruol A; Amadori A; Saggioro D
    Front Oncol; 2019; 9():85. PubMed ID: 30847299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Association between ERCC2, NBN, RAD51 Gene Variants and Osteosarcoma Risk: a Systematic Review and Meta-Analysis.
    Mehdinejad M; Sobhan MR; Mazaheri M; Zare Shehneh M; Neamatzadeh H; Kalantar SM
    Asian Pac J Cancer Prev; 2017 May; 18(5):1315-1321. PubMed ID: 28610420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
    Cao ZH; Yin HP; Jiang N; Yu B
    Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients.
    Zhong G; Li HK; Shan T; Zhang N
    Genet Mol Res; 2015 Dec; 14(4):17228-34. PubMed ID: 26681216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between common polymorphisms in
    Li C; Yu X; Guo D; Liu G; Zhang K; Teng Q; Lin H
    Onco Targets Ther; 2018; 11():3495-3504. PubMed ID: 29950854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
    Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
    Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.